Food and Drug Administration authorization of Pfizer Inc. booster vaccines for more teens took a step forward when the agency said further study by an advisory committee wasn’t necessary.
Third doses for those age 16 and 17 do “not raise questions that would benefit from additional discussion by the members of the committee,” the FDA said in an email.
